跳至主要内容
临床试验/NCT00028353
NCT00028353已完成2 期

A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)

GTx46 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2001年4月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
GTx
入组人数
500
试验地点
46

研究概览

简要总结

If you are a male 30 years of age or older and have a positive diagnosis of high grade (II or III) prostate Intraepithelial Neoplasia (PIN) or have had an abnormal/suspicious prostate biopsy, you may be eligible for this study. This is a study of an investigational medication that may reduce high grade PIN and prevent the occurrence of prostate cancer. This study is currently enrolling up to 500 men at approximately 60 locations in the United States.

详细描述

High grade PIN is the development of precancerous, abnormal tissue of the prostate gland that puts men at high risk of developing prostate cancer. This study will take one year of participation with clinic visits every three months. There will be two prostate biopsies during the study, at six and twelve months. If qualified to participate, you will be randomly assigned to one of four treatment groups. Three out of four groups are varying doses of the study medication and the other is the placebo group (like a sugar pill).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double

入排标准

年龄范围
30 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Must have confirmed high grade PIN on prostate biopsy within past 6 months.
  • Must have a serum PSA <12 ng/ml.
  • Can not have prostate cancer.
  • Have significant ocular opacities.
  • Can not take finasteride or other testosterone like supplement.

排除标准

  • 未提供

研究者

发起方
GTx
申办方类型
Industry

研究点 (46)

Loading locations...

相似试验

A Chemoprevention Study of an Investigational Drug... | 临床试验